Spironolactone Plus Full-Dose ACE Inhibition in Patients With Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?
Pharmaceuticals - Switzerland
doi 10.3390/ph3010001
Full Text
Open PDFAbstract
Available in full text
Date
January 5, 2010
Authors
Publisher
MDPI AG